NASDAQ:ACADACADIA Pharmaceuticals Stock Price, Forecast & News

ACADIA Pharmaceuticals' stock was trading at $36.87 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ACAD stock has increased by 15.9% and is now trading at $42.73.
View which stocks have been most impacted by Coronavirus.

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ACADIA Pharmaceuticals in the last year. There are currently 1 hold rating and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for ACADIA Pharmaceuticals.

ACADIA Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for ACADIA Pharmaceuticals.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) announced its quarterly earnings data on Wednesday, August, 5th. The biopharmaceutical company reported ($0.27) EPS for the quarter, beating analysts' consensus estimates of ($0.44) by $0.17. ACADIA Pharmaceuticals had a negative return on equity of 33.33% and a negative net margin of 57.28%.
View ACADIA Pharmaceuticals' earnings history.

ACADIA Pharmaceuticals issued an update on its FY 2020 After-Hours earnings guidance on Wednesday, August, 5th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $430-450 million, compared to the consensus revenue estimate of $437.26 million.

15 brokers have issued 1-year price objectives for ACADIA Pharmaceuticals' shares. Their forecasts range from $42.00 to $72.00. On average, they expect ACADIA Pharmaceuticals' share price to reach $59.53 in the next year. This suggests a possible upside of 39.3% from the stock's current price.
View analysts' price targets for ACADIA Pharmaceuticals.

Press coverage about ACAD stock has trended negative recently, according to InfoTrie. The research firm identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. ACADIA Pharmaceuticals earned a media sentiment score of -2.0 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days.
View the latest news about ACADIA Pharmaceuticals.

Some companies that are related to ACADIA Pharmaceuticals include Royalty Pharma (RPRX), UCB (UCBJF), Genmab A/S (GMAB), Alexion Pharmaceuticals (ALXN), Genmab A/S (GNMSF), BioMarin Pharmaceutical (BMRN), Shiseido (SSDOY), Beigene (BGNE), Merck KGaA (MKGAF), Alnylam Pharmaceuticals (ALNY), Horizon Therapeutics (HZNP), Catalent (CTLT), Teva Pharmaceutical Industries (TEVA), GRIFOLS S A/S (GRFS) and Sarepta Therapeutics (SRPT).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other ACADIA Pharmaceuticals investors own include Micron Technology (MU), Sarepta Therapeutics (SRPT), Celgene (CELG), Gilead Sciences (GILD), NVIDIA (NVDA), Alibaba Group (BABA), Synergy Pharmaceuticals (SGYP), Netflix (NFLX), Omeros (OMER) and Citigroup (C).

ACADIA Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACAD."

ACADIA Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include First Trust Advisors LP (0.91%), Frontier Capital Management Co. LLC (0.76%), MERIAN GLOBAL INVESTORS UK Ltd (0.68%), Fairmount Funds Management LLC (0.38%), Columbus Circle Investors (0.26%) and Kornitzer Capital Management Inc. KS (0.20%). Company insiders that own ACADIA Pharmaceuticals stock include Austin D Kim, Bros Advisors Lp Baker, Elena Ridloff, Eric Alejandro Miller, James M Daly, Laura Brege, Michael J Yang, Srdjan R Stankovic and Stephen Davis.
View institutional ownership trends for ACADIA Pharmaceuticals.

ACAD stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Frontier Capital Management Co. LLC, Russell Investments Group Ltd., Moody Aldrich Partners LLC, Mackay Shields LLC, Calamos Advisors LLC, International Biotechnology Trust PLC, and Mutual of America Capital Management LLC. Company insiders that have sold ACADIA Pharmaceuticals company stock in the last year include Austin D Kim, Elena Ridloff, Eric Alejandro Miller, James M Daly, Laura Brege, Michael J Yang, Srdjan R Stankovic, and Stephen Davis.
View insider buying and selling activity for ACADIA Pharmaceuticals.

ACAD stock was acquired by a variety of institutional investors in the last quarter, including MERIAN GLOBAL INVESTORS UK Ltd, Columbus Circle Investors, Kornitzer Capital Management Inc. KS, Candriam Luxembourg S.C.A., State Board of Administration of Florida Retirement System, New York State Common Retirement Fund, Sumitomo Mitsui Trust Holdings Inc., and Delta Investment Management LLC.
View insider buying and selling activity for ACADIA Pharmaceuticals.

Shares of ACAD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ACAD stock can currently be purchased for approximately $42.73.

ACADIA Pharmaceuticals has a market capitalization of $6.74 billion and generates $339.08 million in revenue each year. The biopharmaceutical company earns $-235,260,000.00 in net income (profit) each year or ($1.60) on an earnings per share basis. ACADIA Pharmaceuticals employs 465 workers across the globe.

The official website for ACADIA Pharmaceuticals is www.acadia-pharm.com.

ACADIA Pharmaceuticals' mailing address is 3611 VALLEY CENTRE DRIVE SUITE 300, SAN DIEGO CA, 92130. The biopharmaceutical company can be reached via phone at 858-558-2871 or via email at [email protected]